Masoud Dehbozorgi

Dr. Masoud Dehbozorgi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2025 in Heliyon
Verified
Journal Article
Open access
SKSeyede Sara Pakdaman Kolour
Seyede Sara Pakdaman Kolour
SNSaeide Nematollahi
Saeide Nematollahi
MDMasoud Dehbozorgi
Masoud Dehbozorgi
FFFarnaz Fattahi
Farnaz Fattahi
FMFatemeh Movahed
Fatemeh Movahed
BHBahareh Salmanian Hajiagha
Bahareh Salmanian Hajiagha
The primary cause of pain and disability in the world is osteoarthritis (OA), a common joint disease characterized by the primary pathological alteration in articular cartilage deterioration. The general outcome of treatment is not acceptable despite current interventions. Therefore, joint replacement surgery is frequently needed by patients with severe OA. Mesenchymal stem cells (MSCs) have become a practical treatment choice for preclinical and clinical OA palliation in recent years, mainly due to their unique immunomodulatory attributes. Further, attractive candidates for cell-free therapy for OA are MSC-derived extracecellulr vesicles (EVs) that convey bioactive molecules of the original cells, such as microRNAs. These EVs have been shown to significantly influence the regulation of various physiological activities of cells in the joint cavity. Dysregulated miRNAs upregulate the synthesis of enzymes that degrade cartilage, downregulate the expression of components in the cartilage matrix, promote the production of proinflammatory cytokines, induce programmed cell death in chondrocytes, inhibit the process of autophagy in chondrocytes, and participate in pathways related to pain. MiRNAs are also found in extracellular membranous vesicles (EVs), such as exosomes, and play a role in intercellular communication in osteoarthritic joints. Thus, the biosynthesis, chemical makeup, and mechanism of action of miRNAs-enriched EVs in OA are all thoroughly covered in this review. We additionally discussed how miRNA-enriched MSC-EVs might be used therapeutically to change intercellular interaction in OA.

3 August 2024 in Current Problems in Surgery
Verified
Journal Article
Closed access
SSSeyed Amirhossein Salehi
Seyed Amirhossein Salehi
HHHamed Hajishah
Hamed Hajishah
MAMohammad Javad Amini
Mohammad Javad Amini
FMFatemeh Movahed
Fatemeh Movahed
AEAzin Ebrahimi
Azin Ebrahimi
ASArman Shafiee
Arman Shafiee

25 February 2025 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
FAFaezeh Almasi
Faezeh Almasi
FAFaeze Abbasloo
Faeze Abbasloo
NSNarges Soltani
Narges Soltani
MDMasoud Dehbozorgi
Masoud Dehbozorgi
AFAtousa Moghadam Fard
Atousa Moghadam Fard
PRParjin Rahmanpour
Parjin Rahmanpour

15 October 2024 in Discover Medicine
Verified
Journal Article
Open access
PDF file
FMFatemeh Movahed
Fatemeh Movahed
EHEhsan Heidari
Ehsan Heidari
MDMasoud Dehbozorgi
Masoud Dehbozorgi
SGSaba Goodarzi
Saba Goodarzi
FAFatemeh Esmaeilpur Abianeh
Fatemeh Esmaeilpur Abianeh
ASArman Shafiee
Arman Shafiee
Background Statin is a low-cost and easily accessible therapeutic option for COVID-19 patients. Previous observational studies and meta-analyses suggest using statins for COVID-19 patients. Methods Databases including Medline, Scopus, Embase, Cochrane Library, and clinicaltrials.gov were systematically searched. Results After screening 754 records, 9 trials were included. Overall, the study demonstrated a non-significant reduction in all-cause mortality (p = 0.14, RR 0.90, 95% CI 0.79–1.03), no significant difference in the need for mechanical ventilation (p = 0.62, RR 0.95, 95% CI 0.77–1.17), and a non-significant reduction in length of hospitalization (p = 0.71, MD − 0.17 (95% CI − 1.09, 0.76)). The certainty of evidence varied across outcomes, with most demonstrating reasonable certainty. Conclusion Our study did not support clinical efficacy of statins for the treatment of COVID-19.

24 June 2025 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
SGSaba Goodarzi
Saba Goodarzi
ASArman Shafiee
Arman Shafiee
MRMohammad Ali Rafiei
Mohammad Ali Rafiei
MDMasoud Dehbozorgi
Masoud Dehbozorgi
SMSeyed Ali Mofidi
Seyed Ali Mofidi
ASArezou Soltanattar
Arezou Soltanattar